NEWARK, Calif., July 16, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced the appointment of Srinivas G. Rao, MD, PhD, as Chief Medical Officer and Senior Vice President. Dr. Rao has extensive experience and background in pain and central nervous system diseases. He was the Founder and Chief Executive Officer of Kyalin Biosciences, a privately held biotechnology company developing a potential breakthrough therapy for autism, from its formation in 2011 through to its sale to Retrophin, Inc in 2013. In 2014, he served as Executive Vice President and Head of Neuroscience at Retrophin. From 2011 to 2013, Dr. Rao also served as CMO and CSO of 3 companies through his association with Avalon Ventures. Finally, from 2001 to 2011, he was Chief Scientific Officer of Cypress Bioscience where he had a broad range of responsibilities, from business to clinical development. He was the innovator behind Savella™, postulating that this drug's unique pharmacology would be effective for fibromyalgia. Savella™ was approved by the FDA for this indication in 2009.
Dr. Rao received his MD from Yale School of Medicine and his PhD in neurobiology from Yale Graduate School. Dr. Rao is a member of the American College of Neuropharmacology, the American Pain Society, International Association for the Study of Pain and the Society for Neuroscience.
"We are delighted to have Srini join us as Chief Medical Officer", said Jim Schoeneck, President and Chief Executive Officer. "His deep expertise in the areas of pain and neurology and his experience in in-licensing and directing the clinical development and approval of medicines to treat important CNS conditions make him a great fit for Depomed as we seek to expand our franchise in pain and central nervous system diseases."
"I am extremely pleased to be joining Depomed at this exciting time in the company's history," said Dr. Rao. "I believe that Jim and the team at Depomed have accomplished a tremendous amount in the past few years and continue to move towards a leadership position in the field of pain and CNS related products. I look forward to helping the company achieve that goal."